According to the official website of the State Food and drug administration, recently, the World Health Organization said that the domestic bivalent human papillomavirus vaccine (Xinkening) produced by Xiamen Wantai Canghai Biotechnology Co., Ltd ®， Cecolin ®) Formally passed its pre certification for procurement by the United Nations system.
Xinkening bivalent human papillomavirus vaccine (types 16 and 18) is an injectable vaccine. Under the storage condition of 2-8 ℃, the validity period is 24 months.
This time, Xinkening bivalent human papillomavirus vaccine has passed the pre certification of the World Health Organization, becoming the sixth domestic vaccine in China that has passed the pre certification, marking that China's vaccine product supervision, development and production system and product quality have been widely recognized internationally. The vaccination of human papillomavirus vaccine will benefit women all over the world, especially in developing countries, and promote the world health group Organize the realization of the global strategy to accelerate the elimination of cervical cancer.
According to the official website of the State Food and drug administration, human papillomavirus (HPV) vaccine, commonly known as cervical cancer vaccine, can be used to prevent female cervical cancer, male and female genital cancer and genital warts.
Cervical cancer is a relatively high incidence rate of cancer in female malignancies. It seriously threatens women's health. In recent years, the research and development of HPV vaccine in China has made significant progress. In December 30, 2019, the State Food and Drug Administration approved the dual HPV vaccine for Xiamen's Wan Tai Cen Hai Biotechnology Co., Ltd., which was listed as the first domestic HPV vaccine.
Source: People's daily
http://health.people.com.cn/n1/2021/1026/c14739-32264565.html
